The only clinical trial currently that accepts pediatric AML patients is investigating the synergistic effect of azacytidine and enasidenib in myelodysplastic syndrome (MDS) with IDH2 mutation (NCT03383575), whereas there is no ongoing trial in pediatric AML yet. The gene discussed is IDH2; the disease is myelodysplastic syndrome.